Compare EAT & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EAT | DFTX |
|---|---|---|
| Founded | 1975 | N/A |
| Country | United States | United States |
| Employees | N/A | 106 |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 5.9B |
| IPO Year | 1994 | N/A |
| Metric | EAT | DFTX |
|---|---|---|
| Price | $177.39 | $43.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 8 |
| Target Price | ★ $183.00 | $38.50 |
| AVG Volume (30 Days) | 909.3K | ★ 4.7M |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 144.71 | N/A |
| EPS | ★ 7.90 | N/A |
| Revenue | ★ $5,384,200,000.00 | N/A |
| Revenue This Year | $9.00 | N/A |
| Revenue Next Year | $5.49 | N/A |
| P/E Ratio | $22.49 | ★ N/A |
| Revenue Growth | ★ 21.95 | N/A |
| 52 Week Low | $100.30 | $14.62 |
| 52 Week High | $178.25 | $49.20 |
| Indicator | EAT | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 70.06 | 76.29 |
| Support Level | $128.82 | $17.51 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 6.85 | 2.84 |
| MACD | 1.13 | 1.46 |
| Stochastic Oscillator | 97.99 | 80.53 |
Brinker International Inc operates casual dining restaurants under the brand's Chili Grill and Bar (Chili's) and Maggiano's Little Italy (Maggiano's). Chili's falls in the Bar and Grill category of casual dining. Its menu features Fresh Mex and Fresh Tex favorites including signature items such as slow-smoked baby back ribs, craft burgers, fajitas, and bottomless chips and salsa paired with tableside guacamole. Maggiano's is an Italian restaurant brand with a full lunch and dinner menu offering chef-prepared, such as appetizers, chicken, seafood, veal and prime steaks, and desserts. The company generates maximum revenue from Chili's segment.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.